LIFE · Atyr Pharma Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Price · LIFE
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $190.0K | $0 | $0 | - | $0 | $0 | $235.0K | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $7.32M | - | $22.13M | $15.38M | $11.81M | - | $14.81M | $13.97M | $13.36M | - |
| SG&A | $4.12M | - | $4.80M | $4.93M | $3.96M | - | $3.34M | $3.34M | $3.51M | - |
| Total Operating Expenses | $11.44M | - | $26.93M | $20.31M | $15.77M | - | $18.14M | $17.32M | $16.87M | - |
| D&A | $162.0K | - | - | - | $167.0K | - | - | - | $178.0K | - |
| Operating Income | ($11.44M) | - | ($26.75M) | ($20.31M) | ($15.77M) | - | ($18.14M) | ($17.32M) | ($16.64M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($10.79M) | - | ($25.74M) | ($19.53M) | ($14.88M) | - | ($17.26M) | ($16.31M) | ($15.49M) | - |
| EPS - Basic | ($0.11) | - | ($0.26) | ($0.22) | ($0.17) | - | ($0.23) | ($0.23) | ($0.23) | - |
| EPS - Diluted | ($0.11) | - | ($0.26) | ($0.22) | ($0.17) | - | ($0.23) | ($0.23) | ($0.23) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $10.01M | $10.74M | $6.15M | $17.22M | $10.36M | $11.05M | $11.46M | $6.80M | $6.81M | $22.54M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.75M | $3.89M | $4.06M | $3.88M | $1.53M | $4.32M | $3.95M | $1.25M | $4.89M | $3.53M |
| Current Assets | $67.58M | $80.24M | $93.01M | $87.49M | $83.27M | $81.95M | $76.32M | $90.30M | $96.92M | $102.99M |
| Total Assets | $79.65M | $93.00M | $106.65M | $101.53M | $97.25M | $96.83M | $91.62M | $105.94M | $113.25M | $120.65M |
| Current Liabilities | $11.70M | $15.15M | $15.68M | $15.53M | $10.68M | $14.97M | $14.12M | $11.84M | $15.98M | $16.42M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - | - | - | - |
| Stockholders' Equity | $57.93M | $67.48M | $80.23M | $74.84M | $75.05M | $70.02M | $65.33M | $81.61M | $84.47M | $90.66M |
| Retained Earnings | ($616.96M) | ($606.16M) | ($592.20M) | ($566.46M) | ($546.93M) | ($532.05M) | ($517.08M) | ($499.82M) | ($483.51M) | ($468.02M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($12.52M) | - | - | - | ($15.42M) | - | - | - | ($22.38M) | - |
| Investing Cash Flow | $11.49M | - | - | - | ($4.42M) | - | - | - | ($1.36M) | - |
| Financing Cash Flow | ($142.0K) | - | - | - | $18.63M | - | - | - | $7.73M | - |
| CapEx | $138.0K | - | - | - | $0 | - | - | - | $17.0K | - |
| Free Cash Flow | ($12.65M) | - | - | - | ($15.42M) | - | - | - | ($22.40M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | -14076.3% | - | - | - | - | - | -7079.1% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | -7003.4% | - |
| Net margin | - | - | -13549.5% | - | - | - | - | - | -6591.9% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | -9530.6% | - |
| FCF / Net income | 1.17 | - | - | - | 1.04 | - | - | - | 1.45 | - |
| R&D / Revenue | - | - | 11647.4% | - | - | - | - | - | 5686.8% | - |
| SG&A / Revenue | - | - | 2528.9% | - | - | - | - | - | 1492.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -13.5% | - | -24.1% | -19.2% | -15.3% | - | -18.8% | -15.4% | -13.7% | - |
| Return on equity | -18.6% | - | -32.1% | -26.1% | -19.8% | - | -26.4% | -20.0% | -18.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.78 | 5.30 | 5.93 | 5.63 | 7.79 | 5.48 | 5.41 | 7.63 | 6.07 | 6.27 |
| Quick ratio | 5.78 | 5.30 | 5.93 | 5.63 | 7.79 | 5.48 | 5.41 | 7.63 | 6.07 | 6.27 |
| Cash ratio | 0.86 | 0.71 | 0.39 | 1.11 | 0.97 | 0.74 | 0.81 | 0.57 | 0.43 | 1.37 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.37 | 1.38 | 1.33 | 1.36 | 1.30 | 1.38 | 1.40 | 1.30 | 1.34 | 1.33 |
| Liabilities / Assets | - | - | - | - | - | - | - | - | - | - |
| Efficiency | ||||||||||
| Asset turnover | - | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 18.9x | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | -100.0% | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | 5.1% | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 27.5% | - | -47.4% | -17.3% | 5.2% | - | -43.8% | -27.7% | -30.1% | - |
| Net income growth (YoY) | 27.5% | - | -49.2% | -19.8% | 3.9% | - | -52.2% | -32.2% | -29.6% | - |
| EPS growth (YoY) | 35.3% | - | -13.0% | 4.3% | 26.1% | - | -15.0% | -4.5% | 47.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 17.9% | - | - | - | 31.2% | - | - | - | -1119.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -22.8% | -3.6% | 22.8% | -8.3% | -11.1% | -22.8% | -33.6% | -23.2% | -23.1% | 26.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$200.0K totalCollaboration Revenue$200.0K · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing aTYR PHARMA INC against the 5 most active filers in the same SIC group.